Treatment of cancer cell lines with a pharmacological EZH2 inhibitor (EZH2i) promoted antigen-specific T cell killing in vitro, and disruption of EZH2 in mouse models leads to re-establishment of a T cell-mediated anti-tumor response [57]. Here, EZH2 is linked to neoplasm.